Clinical Trials Browser

Phase 1 × OTHER × nilotinib × Clear all

NCT04903119 2026-02-13

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Phase 1 Recruiting

Melanoma

NCT01407198 2025-12-19

Nilotinib With Radiation for High Risk Chordoma

Phase 1 Completed

Chordoma

NCT04205903 2025-06-29

Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer

Phase 1 Completed

11 enrolled 9 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT01702064 2021-01-05

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

Phase 1 Completed

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01155817 2020-04-15

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Phase 1 Completed

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT02225574 2020-02-12

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

Phase 1 Terminated

Other hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myeloid, Chronic-Phase

NCT01871311 2019-02-08

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

Phase 1 Terminated

GastrointestinalHead & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Colorectal Neoplasms